Your browser doesn't support javascript.
loading
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
Rodriguez-Marquez, Paula; Calleja-Cervantes, Maria E; Serrano, Guillermo; Oliver-Caldes, Aina; Palacios-Berraquero, Maria L; Martin-Mallo, Angel; Calviño, Cristina; Español-Rego, Marta; Ceballos, Candela; Lozano, Teresa; San Martin-Uriz, Patxi; Vilas-Zornoza, Amaia; Rodriguez-Diaz, Saray; Martinez-Turrillas, Rebeca; Jauregui, Patricia; Alignani, Diego; Viguria, Maria C; Redondo, Margarita; Pascal, Mariona; Martin-Antonio, Beatriz; Juan, Manel; Urbano-Ispizua, Alvaro; Rodriguez-Otero, Paula; Alfonso-Pierola, Ana; Paiva, Bruno; Lasarte, Juan J; Inoges, Susana; Lopez-Diaz de Cerio, Ascension; San-Miguel, Jesus; Fernandez de Larrea, Carlos; Hernaez, Mikel; Rodriguez-Madoz, Juan R; Prosper, Felipe.
Afiliação
  • Rodriguez-Marquez P; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Calleja-Cervantes ME; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Serrano G; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Oliver-Caldes A; Computational Biology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Palacios-Berraquero ML; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Martin-Mallo A; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
  • Calviño C; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Español-Rego M; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
  • Ceballos C; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Lozano T; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.
  • San Martin-Uriz P; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Vilas-Zornoza A; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Rodriguez-Diaz S; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Martinez-Turrillas R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Jauregui P; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Alignani D; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Viguria MC; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Redondo M; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
  • Pascal M; Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Martin-Antonio B; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.
  • Juan M; Hematology Service, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain.
  • Urbano-Ispizua A; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Rodriguez-Otero P; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Alfonso-Pierola A; Department of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Paiva B; Immunotherapy platform Hospital Sant Joan de Déu, Barcelona, Spain.
  • Lasarte JJ; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Universidad de Barcelona, Barcelona, Spain.
  • Inoges S; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
  • Lopez-Diaz de Cerio A; Hematology and Cell Therapy Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
  • San-Miguel J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Fernandez de Larrea C; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Hernaez M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Rodriguez-Madoz JR; Flow Cytometry Core, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
  • Prosper F; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, Pamplona, Spain.
Sci Adv ; 8(39): eabo0514, 2022 Sep 30.
Article em En | MEDLINE | ID: mdl-36179026
Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study, we address the impact of CAR density on the functionality of BCMA CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with up-regulation of exhaustion markers and increased in vitro cytotoxicity but a decrease in in vivo BM infiltration. Characterization of gene regulatory networks using scRNA-seq identified regulons associated to activation and exhaustion up-regulated in CARHigh T cells, providing mechanistic insights behind differential functionality of these cells. Last, we demonstrate that patients treated with CAR T cell products enriched in CARHigh T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with notable impact on clinical response.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article